These trials concluded at the end of 2021, with results showing great success in reducing body weight
Approval (2017) FDA news release (March 8th, 2024): FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight Weight Regain And Cardiometabolic Effects After Withdrawal Of Semaglutide: The Step 1 Trial Extension (May 19, 2022) US CDC: Adult Activity: An Overview (Dec 20, 2023)
GLP-1 stands for glucagon-like peptide-1, a hormone released after eating that helps regulate appetite, digestion, and blood sugar
: , , ,
The pill can help reduce your appetite, quieten food noise, and make you feel fuller for longer
This is difficult to accomplish with weekly subcutaneous injection, where the peptide is always present at relatively steady-state levels